Yadira Lobaina

Dr. Yadira Lobaina


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YLYadira Lobaina
Yadira Lobaina


1 October 2010 in Viral Immunology
Verified
Journal Article
Closed access
YLYadira Lobaina
Yadira Lobaina
HTHeidy Trujillo
Heidy Trujillo
DGDaymir García
Daymir García
AGAylin Gambe
Aylin Gambe
YCYahima Chacon
Yahima Chacon
JAJulio Cesar Aguilar
Julio Cesar Aguilar
Chronic hepatitis B is a major health problem, with more than 350 million people infected worldwide. Available therapies have limited efficacy and require long-term continuous and expensive treatments, which often lead to the selection of resistant viral variants and rarely eliminate the virus. Immunotherapies have been investigated as a promising new approach. Several vaccine formulations have been clinically tested in chronic patients, none of which have clearly demonstrated efficacy so far. In this study we evaluated a new vaccination strategy comprising the simultaneous co-administration by the nasal and parenteral routes of a multicomponent vaccine formulation in BALB/C and HBsAg-transgenic mice. The formulation under study contains the surface and nucleocapsid antigens of the HBV, and was co-administered by the nasal route and three parenteral routes. For parenteral administration we also evaluated the immunogenicity of the antigenic mixture with alum or without the adjuvant. The immune response was evaluated by ELISA and IFN-γ ELISPOT assays. Our results indicate that all variants generated a strong antibody response in the sera against both antigens, but differed in their capacity to induce cellular immune responses against the surface antigen. Mice immunized by the nasal and subcutaneous routes without alum generated the highest IFN-γ-secreting CD8+ T-cell response, and results in this transgenic mouse model showed that there is no need to include alum. In conclusion, our results indicate that the immunization routes have to be carefully selected before carrying out clinical trials to optimize the immune response and promote further clinical development.

8 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
YLYadira Lobaina
Yadira Lobaina
RCRong Chen
Rong Chen
Edith SuzarteEdith Suzarte
Edith Suzarte
PAPanchao Ai
Panchao Ai
VGVivian Huerta Galindo
Vivian Huerta Galindo
LHLisset Hermida
Lisset Hermida
Despite the rapid development of vaccines against COVID-19, they have important limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal immunity. The present study proposes a potential component for a new generation of vaccines. The recombinant nucleocapsid (N) protein from the SARS-CoV-2 Delta variant was combined with the ODN-39M, a synthetic 39 mer unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), used as an adjuvant. The evaluation of its immunogenicity in Balb/C mice revealed that only administration by intranasal route induced a systemic cross-reactive, cell-mediated immunity (CMI). In turn, this combination was able to induce anti-N IgA in the lungs, which, along with the specific IgG in sera and CMI in the spleen, was cross-reactive against the nucleocapsid protein of SARS-CoV-1. Furthermore, the nasal administration of the N + ODN-39M preparation, combined with RBD Delta protein, enhanced the local and systemic immune response against RBD, with a neutralizing capacity. Results make the N + ODN-39M preparation a suitable component for a future intranasal vaccine with broader functionality against Sarbecoviruses.

1 April 2006 in Vaccine
Verified
Journal Article
Closed access
YLYadira Lobaina
Yadira Lobaina
DPD. Palenzuela
D. Palenzuela
DGD. García
D. García
DRD. Rodríguez
D. Rodríguez
DPD. Pichardo
D. Pichardo
JAJ.C. Aguilar
J.C. Aguilar

28 May 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
YLYadira Lobaina
Yadira Lobaina
RCRong Chen
Rong Chen
Edith SuzarteEdith Suzarte
Edith Suzarte
PAPanchao Ai
Panchao Ai
AMAlexis Musacchio
Alexis Musacchio
LHLisset Hermida
Lisset Hermida
A chimeric protein, formed by two fragments of the conserved nucleocapsid (N) and S2 proteins from SARS-CoV-2, was obtained as a recombinant construct in Escherichia coli. The N fragment belongs to the C-terminal domain whereas the S2 fragment spans the fibre structure in the post-fusion conformation of the spike protein. The resultant protein, named S2NDH, was able to form spherical particles of 10 nm, which forms aggregates upon mixture with the CpG ODN-39M. Both preparations were recognized by positive COVID-19 human sera. The S2NDH + ODN-39M formulation administered by the intranasal route resulted highly immunogenic in Balb/c mice. It induced cross-reactive anti-N humoral immunity in both sera and bronchoalveolar fluids, under a Th1 pattern. The cell-mediated immunity (CMI) was also broad, with positive response even against the N protein of SARS-CoV-1. However, neither neutralizing antibodies (NAb) nor CMI against the S2 region were obtained. As alternative, the RBD protein was included in the formulation as inducer of NAb. Upon evaluation in mice by the intranasal route, a clear adjuvant effect was detected for the S2NDH + ODN-39M preparation over RBD. High levels of NAb were induced against SARS-CoV-2 and SARS-CoV-1. The bivalent formulation S2NDH + ODN-39M + RBD, administered by the intranasal route, constitutes an attractive proposal as booster vaccine of sarbecovirus scope.